Sihuan Pharmaceutical Holdings Group Ltd. and its subsidiaries are delighted to announce that Xuanzhu Biopharmaceutical Co., Ltd. – a non-wholly owned subsidiary of the company – has clinched a major milestone, with the National Medical Products Administration of China issuing a drug registration approval for Anaprozole Sodium Enteric-coated Tablet, the first drug to be approved for marketing by Xuanzhu Biopharm. This breakthrough brings the organization one step closer to launching this treatment for duodenal ulcer, signaling a significant leap from R&D to commercialization.
Anaprozole Sodium Enteric-coated Tablet is set to revolutionize the way we approach digestive issues, as it is the first and only proton pump inhibitor developed fully independently in China. With fast onset, superior stability and a low risk of drug interactions, Anaprozole is becoming a popular choice for Chinese patients.
The drug is metabolized through multiple processes, including both CYP enzymes and non-enzymes, and is excreted through both kidney and gut, which makes it a great choice for those with impaired renal function. The benefits don’t end there: Anaprozole is now being investigated for use in adult reflux esophagitis (RE), and is expected to enter Phase III clinical trials by the end of 2023. Truly, Anaprozole Sodium Enteric-coated Tablet is showing great promise in the field of digestive care.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group, is delighted to announce that Xuanzhu Biopharm’s Anerazole Sodium Enteric-Coated Tablets have been approved, providing much-needed additional treatment options for the millions of Chinese patients suffering from peptic ulcer.
PPI is the number one choice for peptic ulcer due to its wonderful clinical performance, and the approval of Anerazole Sodium Enteric-Coated Tablets is a major step to injecting billions of dollars into the acid suppressant market. With a total market sales size of proton pump inhibitors in China estimated to be an incredible RMB30 billion, the future commercial potential of this new tablet should have vast clinical value.
About Sihuan Pharmaceutical Holdings Group Ltd.
Since its founding in 2001 and listing on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical Holdings Group has emerged as an international leader in medical aesthetics and biopharmaceuticals. Tapping into therapeutic areas such as oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine and industrial hemp, the company has secured a comprehensive, independent production and R&D technology platform, an enviable product pipeline, and a mature sales system. Following its two-wheeled strategy – rapid advancement in the medical aesthetics and biopharmaceutical businesses – the company is on track to becoming a top-tier Chinese medical aesthetics and biopharmaceutical brand.
About Xuanzhu Biopharmaceutical Co., Ltd.
Xuanzhu Biopharmaceutical is an innovative drug subsidiary of Sihuan Pharmaceutical, dedicated to pioneering research and development of life-saving class 1 drugs to address unmet medical needs. With its two R&D platforms – small molecule chemistry and large molecule biologics – and a team of experienced experts in oncology, digestion and non-alcoholic steatohepatitis diseases, Xuanzhu is ready to make an impact in the global pharmaceutical market and contribute to human health.
Driven by a commitment to innovation, and empowering values such as open innovation, courageous commitment, scientific rigor, and overcoming difficulties, Xuanzhu is well on its way to becoming a leading international pharmaceutical company with its own research, production, and sales capabilities.